Saltigo GmbH

Expert Statement: Christoph Schaffrath, Lanxess

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Michael Zobel to Head Lanxess Subsidiary Saltigo

Michael Zobel (50), currently head of the High Performance Materials (HPM) business unit, will take over the management of Lanxess subsidiary Saltigo from Torsten Derr (50) on June 1, 2020.

Modular In Every Respect

“Modular” is currently an often-quoted buzzword in the process industry – in process technology and engineering, automation and supply chain management.

Experts Statements: Dr. Jörg Mohr, Saltigo

Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs.

Saltigo to Invest €60 Million at Leverkusen

Lanxess is investing some €60 million in expanding custom synthesis facilities at multi-purpose production facilities in the Central Organics Pilot Plant (ZeTO) of fine chemicals subsidiary Saltigo in Leverkusen, Germany.

Hubert Fink Named to Lanxess Board

Hubert Fink has been appointed to the Lanxess managing board effective Oct. 1, 2015, increasing the number of board members from three to four.

CPhI 2014 Experts Statements: Jörg Schneider, Head of Marketing, Saltigo

Saltigo: 'Working Proactively With Trends'

Adaptability — A lot has happened in the world of custom manufacturing since Saltigo was carved out of Lanxess' fine chemicals business in 2006.

Saltigo to Relocate Corporate HQ to Leverkusen

In a reshuffle of corporate functions following the relocation of group headquarters from Leverkusen, Germany, to Cologne, Germany, Lanxess is moving the headquarters of fine chemicals subsidiary Saltigo from Langenfeld, Germany, into its recently vacated Leverkusen premises.

Saltigo to Provide Contract Manufacturing Services for Daiichi Sankyo

Saltigo has signed an agreement with Tokyo-based Daiichi Sankyo for the provision of contract manufacturing services; this comes ahead of Daiichi Sankyo's plans to commercialize one of its novel drug pipeline projects.

Saltigo to Actively Develop Attractive Lines of Business

"In the future we will be even better positioned to serve our customers as their partner of choice," says Wolfgang Schmitz, Managing Director of Saltigo, in the run-up to this year's Chemspec Europe tradeshow.

Saltigo Realigns Strategy

Saltigo, the custom manufacturing business of Lanxess' Advanced Intermediates segment, which achieved total sales of €1.5 billion in 2011, has realigned its strategy.

Saltigo Examines the State of Custom Manufacturing in the New Year

Optimism Springs Eternal - 2011 was a year fraught with uncertainties, and many industries are wearily eyeing the year to come.

Saltigo: Joerg Schneider Succeeds Uwe Brunk

Saltigo, a subsidiary of German chemical company Lanxess, has appointed Joerg Schneider as head of its Agro and Fine Chemicals business unit.

Saltigo at the BOS Forum

API Development - Changing demands and requirements in the design and implementation of work programs associated with both non-clinical and clinical phase development of novel APIs is one of the key topics to be covered in the BOS Forum on Sept. 20 at the Royal College of Physicians in London.

Wolfgang Schmitz on 5 Years of Saltigo

Saltigo celebrated its fifth birthday at this year's Chemspec Europe trade show in Geneva.

Saltigo Undertakes Major Expansion of Production

Saltigo, a wholly owned subsidiary of specialty chemicals group Lanxess, is significantly expanding production at its Leverkusen site.

No Surprises!

About a year and a half ago, Saltigo, the globally active custom synthesis business of Germany-based specialty chemicals group Lanxess, launched the "Saltigo Way Forward" project focusing on the optimization of project management and production planning and preparation procedures.

A Peek In the Toolbox

Over the course of previous decades, worldwide research has continued to be focused on increasingly sophisticated novel methods for the development of chiral building blocks.